Christopher Waddick
Director of Finance/CFO at CARDIOL THERAPEUTICS INC.
Net worth: 202 400 $ as of 2024-04-29
Christopher Waddick active positions
| Companies | Position | Start | End |
|---|---|---|---|
| CARDIOL THERAPEUTICS INC. | Director/Board Member | 2022-05-18 | - |
| Director of Finance/CFO | 2018-08-15 | - | |
| Corporate Secretary | 2018-08-15 | - | |
Active Energy, Inc.
 Active Energy, Inc. Electric UtilitiesUtilities Active Energy, Inc. operates as an energy management firm. It offers energy assessment, electricity products and services, natural gas products and services, and cap and trade. The company is headquartered in Burlington, Canada. | Director of Finance/CFO | 2012-12-31 | - |
| President | 2012-12-31 | - | |
| Nrj Consulting, Inc. | President | 2009-10-31 | - |
Career history of Christopher Waddick
Former positions of Christopher Waddick
| Companies | Position | Start | End |
|---|---|---|---|
Vasogen, Inc.
 Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Chief Executive Officer | - | - |
| Chief Operating Officer | 2005-06-30 | 2007-05-31 | |
| Director of Finance/CFO | 2007-05-31 | 2009-10-22 |
Training of Christopher Waddick
| York University | Masters Business Admin |
| Wilfrid Laurier University | Undergraduate Degree |
Statistics
International
| Canada | 6 |
| United States | 2 |
Operational
| Director of Finance/CFO | 3 |
| President | 2 |
| Chief Executive Officer | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
| Utilities | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| CARDIOL THERAPEUTICS INC. | Health Technology |
| Private companies | 3 |
|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
Active Energy, Inc.
Active Energy, Inc. Electric UtilitiesUtilities Active Energy, Inc. operates as an energy management firm. It offers energy assessment, electricity products and services, natural gas products and services, and cap and trade. The company is headquartered in Burlington, Canada. | Utilities |
| Nrj Consulting, Inc. |
- Stock Market
- Insiders
- Christopher Waddick
- Experience